Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 107Colonic Neoplasms 91Pancreatic Neoplasms 88Stomach Neoplasms 75Neoplasm Metastasis 61Esophageal Neoplasms 40Carcinoma, Hepatocellular 31Lymphoma 24Adenocarcinoma Of Esophagus 24Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Adenocarcinoma 19Leukemia 17Cholangiocarcinoma 15Biliary Tract Neoplasms 15Burkitt Lymphoma 14Gastrointestinal Neoplasms 12Lymphoma, Non-Hodgkin 11Osteosarcoma 9Liver Neoplasms 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Peritoneal Neoplasms 8Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Lymphoma, Large B-Cell, Diffuse 7Bile Duct Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Multiple Myeloma 6

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Efficacy and Safety × Leucovorin × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡